1. Home
  2. FMNB vs ALLO Comparison

FMNB vs ALLO Comparison

Compare FMNB & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Farmers National Banc Corp.

FMNB

Farmers National Banc Corp.

HOLD

Current Price

$13.96

Market Cap

555.3M

Sector

Finance

ML Signal

HOLD

Logo Allogene Therapeutics Inc.

ALLO

Allogene Therapeutics Inc.

HOLD

Current Price

$2.24

Market Cap

539.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FMNB
ALLO
Founded
1887
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
555.3M
539.4M
IPO Year
2010
2018

Fundamental Metrics

Financial Performance
Metric
FMNB
ALLO
Price
$13.96
$2.24
Analyst Decision
Hold
Strong Buy
Analyst Count
2
15
Target Price
$15.00
$8.35
AVG Volume (30 Days)
285.3K
14.6M
Earning Date
04-22-2026
05-07-2026
Dividend Yield
4.89%
N/A
EPS Growth
18.85
34.09
EPS
1.45
N/A
Revenue
$279,922,000.00
N/A
Revenue This Year
$52.63
N/A
Revenue Next Year
$8.28
$142,416.42
P/E Ratio
$9.81
N/A
Revenue Growth
3.89
N/A
52 Week Low
$12.23
$0.86
52 Week High
$15.50
$4.46

Technical Indicators

Market Signals
Indicator
FMNB
ALLO
Relative Strength Index (RSI) 53.99 47.37
Support Level $13.04 $2.14
Resistance Level $14.43 $2.71
Average True Range (ATR) 0.35 0.17
MACD -0.02 -0.03
Stochastic Oscillator 38.26 57.04

Price Performance

Historical Comparison
FMNB
ALLO

About FMNB Farmers National Banc Corp.

Farmers National Banc Corp is a one-bank holding company engaged in financial activities, including securities underwriting and dealing, insurance agency and underwriting activities, and merchant banking activities. It operates in the domestic banking, trust, retirement consulting, insurance, and financial management industries. The company has two operating segments of business; the Bank segment, and the Trust segment, out of which the majority of the company's revenue is derived from the bank segment.

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Share on Social Networks: